Abstract 2113P
Background
Cisplatin-induced nephrotoxicity (CIN) is a frequent dose-limiting adverse effect, and many nephroprotective strategies have been proposed to prevent its occurrence. Although multiple studies support premedication with magnesium (Mg) and hydration, this intervention has not been widely implemented, as some centers still replace it only after the occurrence of hypomagnesemia. We performed a systematic review and meta-analysis to evaluate the efficacy and effectiveness of Mg supplementation (suppl) prior to cisplatin.
Methods
We systematically searched Pubmed, Embase, and Cochrane databases for randomized clinical trials (RCT) and observational studies assessing prophylactic Mg suppl compared with placebo for patients receiving cisplatin-based chemotherapy. Primary outcomes were acute nephrotoxicity and hypomagnesemia events; secondary outcome included the association of CIN with variations on serum creatinine levels (ΔSCr). We used RevMan 5.1.7 and RStudio for statistical analysis; random-effects models to pool studies; and I2 statistics to assess heterogeneity.
Results
We included 24 studies with 3,803 patients. Nine were RCT and 15 observational cohort studies. We found a significant reduction of risk of CIN (all grades) in patients treated with prophylactic Mg compared to placebo (OR = 0.16; 95%CI 0.11 – 0.24; p<0.001). The pooled analysis including only studies adjusted for confounding variables demonstrated a 67% risk reduction of CIN with Mg suppl (p<0.0001). Mg prophylaxis was effective in both the clinical trial setting (OR = 0.22) and in the real-world data analysis (OR = 0.15). The benefit was seen across all tumor types and combinations of cisplatin-based chemotherapies included in the study. Hypomagnesemia events were significantly less frequent in the intervention group (OR = 0.27; 95%CI 0.16–0.45; p<0.000001). There was no difference regarding doses of Mg administered, and the ΔSCr were not significantly associated with the risk of CIN.
Conclusions
In patients undergoing cisplatin-based chemotherapy, prophylactic Mg suppl significantly reduces the risk of CIN and hypomagnesemia as compared with no prophylaxis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06
2115P - Pre-cachexia incidence in patients with solid cancer: A cross-sectional study
Presenter: Lynn Gottmann
Session: Poster session 06